نتایج جستجو برای: primary progressive ms
تعداد نتایج: 862134 فیلتر نتایج به سال:
BACKGROUND A month-of-birth (MOB) effect has been shown in multiple sclerosis (MS). METHODS Our chi(2) analyses looked at whether this MOB effect differed by MS phenotype ("bout onset," "primary progressive"). RESULTS The MOB effect was derived from "bout onset" MS patients (May/November ratio = 1.43; chi(2) = 17.32, df = 1, p = 0.000032). CONCLUSIONS An unspecified environmental effect i...
BACKGROUND Treatment with MD1003 (high-dose biotin) showed promising results in progressive multiple sclerosis (MS) in a pilot open-label study. OBJECTIVE To confirm the efficacy and safety of MD1003 in progressive MS in a double-blind, placebo-controlled study. METHODS Patients (n = 154) with a baseline Expanded Disability Status Scale (EDSS) score of 4.5-7 and evidence of disease worsenin...
Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients with Multiple Sclerosis
BACKGROUND Soluble CD163 (sCD163) is a macrophage specific protein known to be up-regulated in serum from patients with multiple sclerosis (MS). OBJECTIVE To investigate sCD163 in serum and CSF (cerebrospinal fluid) from patients undergoing MS diagnostic work-up and analyse its potential as a diagnostic biomarker. METHODS After a full MS diagnostic work-up, including collection of paired sa...
Late onset multiple sclerosis (LOMS) is when the first symptom starts after 50 years of age, representing 4.5% of multiple sclerosis (MS) patients. This study describes the clinical characteristics of patients with LOMS followed at a specialized MS center in São Paulo. Data was obtained from medical records of 742 patients with MS. The LOMS frequency was 4.18%, median age at onset was 54 years ...
10.2217/14750708.5.5.605 © 2 Multiple sclerosis (MS) is a chronic and debilitating disease affecting approximately 2.5 million people worldwide, and safe and effective treatment options are sorely lacking. While there are several currently approved drugs that have shown some efficacy at reducing the relapse rate in patients with the relapsing–remitting form of the disease, the impact of this ou...
Progressive multiple sclerosis (MS) is characterized clinically by the accumulation of neurological disability without unequivocal recovery. Understanding the mechanisms that determine entering in this stage of the disease is a great challenge in order to identify potential therapeutic targets. Recent advances in defining more accurately the progressive phenotype of MS, have concluded that diff...
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, with unknown etiology in which both genetic and environmental factors are thought to be involved. The human leukocyte antigen (HLA) system provides a set of genetic markers which lend themselves to systematic study. In Iran, HLA-A24, HLA-DR2, and HLADR15 are significantly increased in MS patients. The disease also...
BACKGROUND AND PURPOSE Olfactory bulb atrophy is associated with cognitive dysfunction in Parkinson's and Alzheimer's disease, and with major depression. It has been suggested that olfactory bulb atrophy or dysfunction is therefore a marker of neurodegeneration. Multiple sclerosis (MS) is now also recognized as having a significant neurodegenerative component. Thus, the aim of this study was to...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید